Parabilis Medicine is a clinical stage biotech company using its proprietary Helicon platform to reach “undruggable” cancer targets. By combining AI and physics based modeling, they have developed special peptides that can enter cells to block proteins that existing drugs cannot reach. Their proprietary drug FOG-001(zolucatetide), is a first of its kind therapy designed to inhibit a key driver in colorectal and desmoid tumors.

The new capital will be used to advance its proprietary drug, FOG-001. This drug is able to directly inhibit the β-catenin:TCF interaction, a pathway linked to millions of cancer cases but previously unable to be targeted. Parabilis aims to advance towards a registrational trial for desmoid tumors and explore its use in other cancers such as colorectal and liver cancer. The company will also further develop it’s helicon peptide platform, specifically focusing on its prostate cancer programs and other previously untargeted cancer diseases.

FOG-001 has proven itself successful in the treatment of five different tumor types, including rare conditions like adamantinomatous craniopharyngioma(ACP) and desmoid tumors. Parabilis is also slated to release new clinical evidence on FOG-001’s potential in the treatment of hepatocellular carcinoma (HCC) and familial adenomatous polyposis (FAP).

Most disease driving proteins are “flat” where small molecules cannot bind effectively. Parabilis’s Helicon peptides act as a “middle man” to enter cells and bind to these difficult surfaces, treating cancers that are previously untreatable.

Parabilis’s advancements in cancer treatment is definitely a ray of hope for those suffering with cancer.